PROC Stock Overview
Procaps Group S.A. develops, produces, and markets pharmaceutical solutions worldwide.
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 1/6 |
| Past Performance | 1/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Procaps Group S.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$2.71 |
| 52 Week High | US$5.00 |
| 52 Week Low | US$1.95 |
| Beta | 0.13 |
| 1 Month Change | -12.72% |
| 3 Month Change | -35.40% |
| 1 Year Change | -45.80% |
| 3 Year Change | -73.03% |
| 5 Year Change | n/a |
| Change since IPO | -72.46% |
Recent News & Updates
These 4 Measures Indicate That Procaps Group (NASDAQ:PROC) Is Using Debt Extensively
Mar 28
Is Procaps Group S.A. (NASDAQ:PROC) Worth US$3.7 Based On Its Intrinsic Value?
Feb 02Recent updates
These 4 Measures Indicate That Procaps Group (NASDAQ:PROC) Is Using Debt Extensively
Mar 28Is Procaps Group S.A. (NASDAQ:PROC) Worth US$3.7 Based On Its Intrinsic Value?
Feb 02Calculating The Intrinsic Value Of Procaps Group S.A. (NASDAQ:PROC)
Feb 01Procaps Group reports Q2 results
Aug 30Calculating The Fair Value Of Procaps Group, S.A. (NASDAQ:PROC)
Jan 10Shareholder Returns
| PROC | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 4.2% | -1.5% | -3.2% |
| 1Y | -45.8% | 9.7% | 19.3% |
Return vs Industry: PROC underperformed the US Pharmaceuticals industry which returned 9.7% over the past year.
Return vs Market: PROC underperformed the US Market which returned 19.3% over the past year.
Price Volatility
| PROC volatility | |
|---|---|
| PROC Average Weekly Movement | 10.5% |
| Pharmaceuticals Industry Average Movement | 9.8% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.5% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: PROC's share price has been volatile over the past 3 months.
Volatility Over Time: PROC's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1977 | 5,500 | Jose Antonio Vieira | www.procapsgroup.com |
Procaps Group S.A. develops, produces, and markets pharmaceutical solutions worldwide. The company formulates, manufactures, and markets branded prescription drugs in various therapeutic areas, including feminine care products, pain relief, skin care, digestive health, growth and development, cardiology, vision care, central nervous system, and respiratory. It also provides drugs for hospital use, such as antibiotic, blood clot, personal protective equipment, immunosuppressant, oncology, and analgesics products.
Procaps Group S.A. Fundamentals Summary
| PROC fundamental statistics | |
|---|---|
| Market cap | US$305.75m |
| Earnings (TTM) | US$52.20m |
| Revenue (TTM) | US$414.10m |
5.9x
P/E Ratio0.7x
P/S RatioIs PROC overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PROC income statement (TTM) | |
|---|---|
| Revenue | US$414.10m |
| Cost of Revenue | US$186.19m |
| Gross Profit | US$227.91m |
| Other Expenses | US$175.71m |
| Earnings | US$52.20m |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.46 |
| Gross Margin | 55.04% |
| Net Profit Margin | 12.61% |
| Debt/Equity Ratio | 663.2% |
How did PROC perform over the long term?
See historical performance and comparison